What are the major opportunities in the Short Acting B2 Agonists market? What are the strategies for the Short Acting B2 Agonists market?

For detailed insights on the major opportunities and strategies in the Short Acting B2 Agonists market, Read More

How does the Short Acting B2 Agonists market relate to the overall economy and other similar markets?

For detailed insights on Short Acting B2 Agonists's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Short Acting B2 Agonists market growth? SWOT analysis of the Short Acting B2 Agonists market.

For detailed insights on the key dynamics influencing the Short Acting B2 Agonists market growth and SWOT analysis of the Short Acting B2 Agonists industry, Read More

Global Short-Acting B2 Agonists Market Report 2025

Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Short-Acting B2 Agonists Global Market Report 2025

Name: Short-Acting B2 Agonists Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Type (Albuterol, Levalbuterol, Metaproterenol, Other Types), By Indication (Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm), By Administration Route (Inhalation, Oral, Injection), By End User (Hospitals, Clinics, Home Healthcare Settings) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Short-Acting B2 Agonists Market Overview

• Short-Acting B2 Agonists market size has reached to $4.25 billion in 2024

• Expected to grow to $5.18 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%

• Growth Driver: Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief

• Market Trend: Advancements In Inhaler Technology For Efficient Acute Symptom Management

• North America was the largest region in 2024.

What Is Covered Under Short-Acting B2 Agonists Market?

Short-acting beta-2 agonists are a class of medications commonly used to provide quick relief from symptoms of asthma and other respiratory conditions. These drugs work by stimulating beta-2 adrenergic receptors in the smooth muscle lining of the airways, leading to rapid bronchodilation or relaxation of the muscles around the airways.

The main short-acting b2 agonists type include albuterol, levalbuterol, metaproterenol, and others. Albuterol refers to a widely used short-acting B2 agonist that provides rapid relief from bronchospasm by relaxing airway muscles. It is used for asthama, chronic obstructive pulmonary disease (copd), and exercise-induced bronchospasm and can be administered through inhalation, oral, and injection routes. It is used by various end users such as hospitals, clinics, and home healthcare settings.

Short-Acting B2 Agonists Market Size and growth rate 2025 to 2029: Graph

What Is The Short-Acting B2 Agonists Market Size 2025 And Growth Rate?

What Is The Short-Acting B2 Agonists Market Growth Forecast?

The short-acting B2 agonist market size is expected to see steady growth in the next few years. It will grow to $5.18 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising prevalence of asthma and chronic obstructive pulmonary disease, increasing awareness about asthma management, increasing government initiatives for asthma and copd treatment, rising healthcare expenditure globally, and expanding geriatric population. Major trends in the forecast period include advancements in inhaler technologies, expanding market for personalized asthma treatments, convenient drug delivery systems, technological advancements in nebulizers for home use, and improvements in drug formulation for better efficacy.

The forecast of 4.1% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden asthma patients by driving up costs of albuterol inhalers manufactured in India and Spain, resulting in reduced respiratory emergency preparedness and higher pulmonary disease management expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Short-Acting B2 Agonists Market Segmented?

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Is Driving The Short-Acting B2 Agonists Market? Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the short-acting B2 agonists market going forward. Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes breathing difficulties and reduced airflow, mainly due to prolonged exposure to harmful gases or cigarette smoke. The rise in chronic obstructive pulmonary disease (COPD) is due to increasing exposure to air pollution, as long-term inhalation of pollutants like particulate matter and toxic gases can harm lung tissue and accelerate the disease's development. Short-acting ß2-agonists (SABAs) are used in COPD to quickly relieve symptoms like shortness of breath by relaxing airway muscles. They act as rescue medications during flare-ups but are not meant for long-term control. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, chronic obstructive pulmonary disease (COPD) accounted for 7,691 deaths, or 29.6 per 100,000 population, representing 4.0% of all fatalities. Therefore, the increasing prevalence of chronic obstructive pulmonary disease will boost the growth of the short-acting B2 agonists industry.

Who Are The Major Players In The Global Short-Acting B2 Agonists Market?

Major companies operating in the short-acting B2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

What Are The Key Trends Of The Global Short-Acting B2 Agonists Market? Advancements In Inhaler Technology For Efficient Acute Symptom Management

Major companies in the short-acting B2 agonists market are focusing on developing technologically advanced products, such as pressurized metered-dose inhalers (pMDI), to help manage acute symptoms efficiently. Pressurized metered-dose inhalers (pMDIs) are handheld devices that deliver a specific dose of medication to the lungs in aerosol form using a propellant-driven spray commonly used for treating respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation. It contains albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. This unique combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Short-Acting B2 Agonists Market? Teva Pharmaceutical Industries Collaborates With Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Inhaler

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based manufacturer of short-acting B2 agonists, collaborated with Launch Therapeutics Inc. to help expedite Teva's ICS clinical research program-SABA (TEV-'248). With this collaboration, Teva Pharmaceutical Industries aims to accelerate the development and commercialization of its innovative dual-action asthma rescue inhaler to provide a more effective treatment option for adult and pediatric asthma patients. Launch Therapeutics Inc. is a US-based clinical development company.

What Is The Regional Outlook For The Global Short-Acting B2 Agonists Market?

North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Short-Acting B2 Agonists Market?

The short-acting beta-2 agonists market consists of sales of nebulizer solutions, combination inhalers, respiratory monitoring devices, spacers and holding chambers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Short-Acting B2 Agonists Industry?

The short-acting b2 agonists market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting b2 agonists industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Short Acting B2 Agonists Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$4.4 billion
Revenue Forecast In 2034	$5.18 billion
Growth Rate	CAGR of 4.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The short-acting B2 agonists market covered in this report is segmented – 1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types 2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm 3) By Administration Route: Inhalation, Oral, Injection 4) By End User: Hospitals, Clinics, Home Healthcare Settings Subsegments: 1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups 2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions 3) By Metaproterenol: Inhalers, Syrups 4) By Other Types: Terbutaline, Pirbuterol, Salbutamol
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Short-Acting B2 Agonists Market Characteristics

3. Short-Acting B2 Agonists Market Trends And Strategies

4. Short-Acting B2 Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Short-Acting B2 Agonists Growth Analysis And Strategic Analysis Framework

5.1. Global Short-Acting B2 Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Short-Acting B2 Agonists Market Growth Rate Analysis

5.4. Global Short-Acting B2 Agonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Short-Acting B2 Agonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Short-Acting B2 Agonists Total Addressable Market (TAM)

6. Short-Acting B2 Agonists Market Segmentation

6.1. Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Albuterol

Levalbuterol

Metaproterenol

Other Types

6.2. Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Asthama

Chronic Obstructive Pulmonary Disease (COPD)

Exercise-Induced Bronchospasm

6.3. Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inhalation

Oral

Injeaction

6.4. Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Home Healthcare Settings

6.5. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inhalers

Nebulizers

Tablets

Syrups

6.6. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inhalers

Nebulizers

Oral Solutions

6.7. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inhalers

Syrups

6.8. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Terbutaline

Pirbuterol

Salbutamol

7. Short-Acting B2 Agonists Market Regional And Country Analysis

7.1. Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short-Acting B2 Agonists Market

8.1. Asia-Pacific Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short-Acting B2 Agonists Market

9.1. China Short-Acting B2 Agonists Market Overview

9.2. China Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short-Acting B2 Agonists Market

10.1. India Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short-Acting B2 Agonists Market

11.1. Japan Short-Acting B2 Agonists Market Overview

11.2. Japan Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short-Acting B2 Agonists Market

12.1. Australia Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short-Acting B2 Agonists Market

13.1. Indonesia Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short-Acting B2 Agonists Market

14.1. South Korea Short-Acting B2 Agonists Market Overview

14.2. South Korea Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short-Acting B2 Agonists Market

15.1. Western Europe Short-Acting B2 Agonists Market Overview

15.2. Western Europe Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short-Acting B2 Agonists Market

16.1. UK Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short-Acting B2 Agonists Market

17.1. Germany Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short-Acting B2 Agonists Market

18.1. France Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short-Acting B2 Agonists Market

19.1. Italy Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short-Acting B2 Agonists Market

20.1. Spain Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short-Acting B2 Agonists Market

21.1. Eastern Europe Short-Acting B2 Agonists Market Overview

21.2. Eastern Europe Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short-Acting B2 Agonists Market

22.1. Russia Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short-Acting B2 Agonists Market

23.1. North America Short-Acting B2 Agonists Market Overview

23.2. North America Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short-Acting B2 Agonists Market

24.1. USA Short-Acting B2 Agonists Market Overview

24.2. USA Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short-Acting B2 Agonists Market

25.1. Canada Short-Acting B2 Agonists Market Overview

25.2. Canada Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short-Acting B2 Agonists Market

26.1. South America Short-Acting B2 Agonists Market Overview

26.2. South America Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short-Acting B2 Agonists Market

27.1. Brazil Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short-Acting B2 Agonists Market

28.1. Middle East Short-Acting B2 Agonists Market Overview

28.2. Middle East Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short-Acting B2 Agonists Market

29.1. Africa Short-Acting B2 Agonists Market Overview

29.2. Africa Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short-Acting B2 Agonists Market Competitive Landscape And Company Profiles

30.1. Short-Acting B2 Agonists Market Competitive Landscape

30.2. Short-Acting B2 Agonists Market Company Profiles

30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Short-Acting B2 Agonists Market Other Major And Innovative Companies

31.1. Perrigo Company plc

31.2. Aurobindo Pharma Ltd.

31.3. Chiesi Farmaceutici S.p.A.

31.4. Cipla Limited

31.5. Hikma Pharmaceuticals PLC

31.6. Amneal Pharmaceuticals Inc.

31.7. Lupin Limited

31.8. Orion Corporation

31.9. Beximco Pharmaceuticals Ltd.

31.10. Micro Labs Limited

31.11. Neuland Laboratories Limited

31.12. Vectura Group plc

31.13. Nephron Pharmaceuticals Corporation

31.14. AdvaCare Pharma USA LLC

31.15. Midas Care Pharmaceuticals Pvt Ltd.

32. Global Short-Acting B2 Agonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short-Acting B2 Agonists Market

34. Recent Developments In The Short-Acting B2 Agonists Market

35. Short-Acting B2 Agonists Market High Potential Countries, Segments and Strategies

35.1 Short-Acting B2 Agonists Market In 2029 - Countries Offering Most New Opportunities

35.2 Short-Acting B2 Agonists Market In 2029 - Segments Offering Most New Opportunities

35.3 Short-Acting B2 Agonists Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: AstraZeneca plc Financial Performance

Table 80: Novartis AG Financial Performance

Table 81: GlaxoSmithKline plc Financial Performance

Table 82: Teva Pharmaceutical Industries Ltd. Financial Performance

Table 83: Apotex Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: AstraZeneca plc Financial Performance

Figure 80: Novartis AG Financial Performance

Figure 81: GlaxoSmithKline plc Financial Performance

Figure 82: Teva Pharmaceutical Industries Ltd. Financial Performance

Figure 83: Apotex Inc. Financial Performance

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Muscarinic Acetylcholine Receptor Global Market Report 2025 – By Type (M1, M4, M5, Other Types ), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Specialty Centers ), By Application (Ch...

GLP-1 Receptor Agonist Global Market Report 2025 – By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs ), By Route Of Administration (Parenteral, Oral ), By End Users (Hospitals, Surgical Clinic...

Extended-Release Drugs Global Market Report 2025 – By Type (Sustained Release Drug, Controlled Release Drug), By Mode (Over-The-Counter, Prescription), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mai...

Active Pharmaceutical Ingredients Global Market Report 2025 – By Type (Innovative APIs (Active Pharmaceutical Ingredient), Generic APIs (Active Pharmaceutical Ingredient)), By Manufacturer (Captive Manufacturers, Merchan...

Chemical Auxiliary Agents Global Market Report 2025 – By Agent (Dispersing Agents, Separation Agents, Solvents), By Application (Technical Textiles, Home Furnishings, Apparel), By Industry (Construction, Paint, Paper, Te...

mTOR Inhibitors Global Market Report 2025 – By Product Type (Rapamune, Afinitor, Torisel, Zortress, Other Product Types), By Indication (Oncology, Immunosuppressant, Organ Transplantation, Other Indications), By Route of...

Small Molecule Active Pharmaceutical Ingredient Global Market Report 2025 – By Type (Synthetic, Chemical, Biological), By Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular...

Frequently Asked Questions

What is the definition of the Short-Acting B2 Agonists market?

How will the Short-Acting B2 Agonists market drivers and restraints affect the market dynamics? What forces will shape the Short-Acting B2 Agonists industry going forward?

The market major growth driver - Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Short-Acting B2 Agonists market?

The short-acting B2 agonist market size has grown steadily in recent years. It will grow from $4.25 billion in 2024 to $4.4 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to growth in the pediatric asthma population, increasing prevalence of environmental allergens, rising urbanization and pollution levels, rising focus on the prevention of asthma exacerbations, and growing number of research and development initiatives. The short-acting B2 agonist market size is expected to see steady growth in the next few years. It will grow to " $5.18 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising prevalence of asthma and chronic obstructive pulmonary disease, increasing awareness about asthma management, increasing government initiatives for asthma and copd treatment, rising healthcare expenditure globally, and expanding geriatric population. Major trends in the forecast period include advancements in inhaler technologies, expanding market for personalized asthma treatments, convenient drug delivery systems, technological advancements in nebulizers for home use, and improvements in drug formulation for better efficacy. For further insights on this market, request a sample here

How is the Short-Acting B2 Agonists market segmented?

The short-acting b2 agonists market covered in this report is segmented –
1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types
2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
3) By Administration Route: Inhalation, Oral, Injection
4) By End User: Hospitals, Clinics, Home Healthcare Settings Subsegments:
1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups
2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions
3) By Metaproterenol: Inhalers, Syrups
4) By Other Types: Terbutaline, Pirbuterol, Salbutamol For further insights on this market, request a sample here

Which region has the largest share of the Short-Acting B2 Agonists market? What are the other regions covered in the report?

North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in the short-acting B2 agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Short-Acting B2 Agonists market?

What are the key trends in the Short-Acting B2 Agonists market?

Major trends in this market include Advancements In Inhaler Technology For Efficient Acute Symptom Management. For further insights on this market, request a sample here.

Book your 30 minutes free consultation with our research experts

Short-Acting B2 Agonists Global Market Report 2025

Short-Acting B2 Agonists Market Overview

What Is Covered Under Short-Acting B2 Agonists Market?

What Is The Short-Acting B2 Agonists Market Size 2025 And Growth Rate?

What Is The Short-Acting B2 Agonists Market Growth Forecast?

What’s The Trade War Impact On Pharmaceuticals Industry?

How Is The Short-Acting B2 Agonists Market Segmented?

What Is Driving The Short-Acting B2 Agonists Market? Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief

Who Are The Major Players In The Global Short-Acting B2 Agonists Market?

What Are The Key Trends Of The Global Short-Acting B2 Agonists Market? Advancements In Inhaler Technology For Efficient Acute Symptom Management

What Are Latest Mergers And Acquisitions In The Short-Acting B2 Agonists Market? Teva Pharmaceutical Industries Collaborates With Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Inhaler

What Is The Regional Outlook For The Global Short-Acting B2 Agonists Market?

What Defines the Short-Acting B2 Agonists Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Short-Acting B2 Agonists Industry?

Short Acting B2 Agonists Market Report Forecast Analysis

Table Of Contents

List Of Tables

List Of Figures

Frequently Asked Questions